Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.31 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | ITGAL | P20701 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9532960 | 0.79 | TSHR (0.37) | MEN1TP53MAPTTSHRMAPK1 | |
| SCHEMBL9533644 | 0.75 | HTR2C (0.40) | MEN1TP53MAPTTSHRMAPK1 | |
| SCHEMBL7300502 | 0.75 | TSHR (0.37) | MEN1TP53MAPTTSHRMAPK1 | |
| SCHEMBL7300349 | 0.75 | SLC6A2 (0.33) | TP53HTR2CHTR2B | |
| SCHEMBL7293466 | 0.75 | KDM4E (0.34) | TP53MAPTHTR2CHTR2B | |
| SCHEMBL9531180 | 0.74 | MEN1 (0.34) | MEN1TP53MAPTTSHRMAPK1 | |
| SCHEMBL7134096 | 0.73 | MAPT (0.49) | MEN1TP53MAPTKMT2AHTR2B | |
| SCHEMBL7294557 | 0.73 | HTR2C (0.42) | MAPTHTR2C | |
| SCHEMBL7294955 | 0.73 | HTR2C (0.42) | TP53MAPTHTR2C | |
| SCHEMBL2350567 | 0.73 | BACE1 (0.36) | MAPTHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | claimed |
| EP-2440517-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-04-18 | — | — | EP | claimed |
| WO-2010144378-A2 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD COLORADO, INC. (US) | 2010-12-16 | — | — | WO | claimed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | claimed |
| EP-4013742-A1 | ANTIMALARIAL AGENTS | Merck Sharp & Dohme Corp. (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021027502-A1 | ANTIMALARIAL AGENTS | MERCK SHARP & DOHME CORP. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-2794563-B1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-9255090-B2 | Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-02-09 | — | — | US | disclosed |
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9029400-B2 | 5-oxoisoxazoles as inhibitors of lipases and phospholipases | SANOFI (FR) | 2015-05-12 | — | — | US | disclosed |
| EP-2794563-A1 | HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2014-10-29 | — | — | EP | disclosed |
| EP-2440517-B1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-03-26 | — | — | EP | disclosed |
| CN-1023319-C | 1 H-imidazole-5-carboxylic acid derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1993-12-29 | — | — | CN | disclosed |
| EP-0314852-B1 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA GEIGY AG (CH) | 1993-11-18 | — | — | EP | disclosed |
| US-5260444-A | Cardiovascular, hypotensive | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-11-09 | — | — | US | disclosed |
| US-5208245-A | Hypotensive agents | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-05-04 | — | — | US | disclosed |
| EP-0460418-A2 | Novel Dihydropyridine derivative | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1991-12-11 | — | — | EP | disclosed |
| US-4921955-A | Process for the synthesis of 1-substituted imidazole-5-carboxylic acids and carboxylic acid derivatives | CIBA-GEIGY CORPORATION (US) | 1990-05-01 | — | — | US | disclosed |
| EP-0314852-A2 | Process for the preparation of 1-substituted imidazole-carbonic acid and derivatives | CIBA-GEIGY AG (CH) | 1989-05-10 | — | — | EP | disclosed |
| CN-87100994-A | 1H-Imidazole-5-carboxylic acid derivatives | — | 1987-09-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150252036-A1 | Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators | PTGDR, PTGER1, PTGDR2 | MEN1 2511/4885TP53 3779/4885MAPT 4848/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | MEN1 4357/4885TP53 2261/4885MAPT 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.